Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults with Severe Immunoglobulin E (IgE)-Mediated Food Allergy
This research study is for adults in the UK who have severe food allergies, specifically those caused by IgE antibodies, and are already receiving Dupilumab treatment. The study is investigating a new medication called Linvoseltamab, which will be given in the short-term alongside their existing Dupilumab. The main goal is to understand how this new medicine works in the body and to check for any side effects. This is a very early stage of testing, often called a 'Phase I' study, where a new medicine is given to people for the first time. The hope is to find better ways to manage severe food allergies and hopefully reduce life-threatening reactions.
At a glance
What is this study about?
This study is all about helping adults who live with severe food allergies. We know that these allergies can be really serious, sometimes even life-threatening, and greatly affect daily life. Many people with severe food allergies are already treated with a medicine called Dupilumab, which helps to calm down the body's allergic response. This study wants to see if adding a new medicine, called Linvoseltamab, for a short period could make their treatment even more effective.
Imagine your body's immune system as a security system. In someone with a severe food allergy, this system sometimes overreacts to certain foods by producing something called IgE antibodies, leading to an allergic reaction. Dupilumab works by helping to reset part of that overactive security system. Linvoseltamab is another type of medicine that might help in a different way, working alongside Dupilumab.
Because this is an early-stage study (called a Phase I study), the main focus is on carefully checking how Linvoseltamab works in the body, what dose might be best, and if it's safe when added to Dupilumab. It's an important step in figuring out if this new medicine could eventually become a helpful treatment option for people with severe food allergies. By taking part, volunteers help researchers understand more about these complex allergies and develop new treatments.
Key takeaways
- This study is for adults with severe IgE-mediated food allergies.
- It tests a new medicine, Linvoseltamab, alongside ongoing Dupilumab treatment.
- The main goal is to check safety and how the new medicine works.
- It's an early-stage study, helping to develop future treatments.
- Participation involves short-term treatment and regular check-ups.
Who may be eligible?
This study is specifically looking for adults aged 18 and over. There is no upper age limit, so suitable individuals of any adult age can take part.
To be considered for this study, you must have a severe food allergy that is known to be linked to something called IgE (Immunoglobulin E). This is a common type of food allergy where your body's immune system overreacts. You must also already be taking Dupilumab as part of your regular treatment for this allergy.
Both men and women are welcome to participate in this study. The research team will carefully check other aspects of your health to make sure that taking part is safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a severe food allergy that involves IgE?
- Are you currently receiving Dupilumab treatment for your food allergy?
- Are you able to attend regular study appointments?
What does participation involve?
If you decide to take part in this study, you would first have a screening visit to make sure it's the right study for you. During the study, you would continue to take your regular Dupilumab treatment. The new medicine, Linvoseltamab, would be given to you for a short time, likely through injections. You would need to attend several appointments at the study clinic for these treatments, and to have various checks and tests. These might include blood tests, physical examinations, and questions about how you're feeling and any symptoms you might have. You'll also have follow-up visits after the Linvoseltamab treatment ends to monitor your health. The total duration of your involvement, from the first screening visit to the final follow-up, will be explained in detail by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What kind of food allergies is this study for?
This study is for adults with severe food allergies that involve IgE antibodies, which is a common type of allergy.
Do I have to be on any other medication to join?
Yes, you must already be receiving Dupilumab treatment for your food allergy to be eligible for this study.
What is Linvoseltamab?
Linvoseltamab is a new medicine being tested. It might help manage severe food allergies when used with Dupilumab.
How long will I be involved in the study?
The exact duration will be explained by the study team, but you will have short-term treatment with Linvoseltamab and then follow-up appointments.
Will I have to pay to take part?
No, taking part in a clinical trial should not cost you anything. All study-related treatments and tests are provided free of charge.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.